FAQ

Imatinib mesylate:MCnc:Pt:Ser/Plas:Qn

Known as: Imatinib mésylate [Masse/Volume] Sérum/Plasma ; Numérique, Imatinib mesylate:Mass Concentration:Point in time:Serum/Plasma:Quantitative, Imatinib mesylate [Mass/volume] in Serum or Plasma 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2012
01220042012

Related topics

Related topics

4 relations
Imatinib mesylatePlasSerumUnit of Mass Concentration

Related mentions per year

Related mentions per year

1936-2018
19401960198020002020
Imatinib mesylate:MCnc:Pt:Ser/Plas:Qn
Serum
Imatinib mesylate
Unit of Mass Concentration
Plas

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Imatinib-ULS-lysozyme: a proximal tubular cell-targeted conjugate of imatinib for the treatment of renal diseases.
The anticancer drug imatinib is an inhibitor of the platelet-derived growth factor receptor (PDGFR) kinases, which are involved… (More)
  • figure 1
  • figure 3
  • figure 2
  • figure 5
  • figure 4
Is this relevant?
2010
2010
Differential effects of ketoconazole and primaquine on the pharmacokinetics and tissue distribution of imatinib in mice.
Imatinib, a selective inhibitor of c-KIT and Bcr-Abl tyrosine kinases, approved for the treatment of chronic myelogenous leukemia… (More)
Is this relevant?
2010
2010
HPLC determination of imatinib in plasma and tissues after multiple oral dose administration to mice.
Imatinib inhibits Bcr-Abl, c-KIT and PDGFR kinases. It is approved for the treatment of chronic myeloid leukemia (CML… (More)
Is this relevant?
2004
2004
Intrapatient consistency of imatinib pharmacokinetics (PK) in patients (pts) with advanced cancers.
2081 Background: Imatinib (STI-571), approved for treatment of CML & GIST, is administered as daily PO therapy and is primarily… (More)
Is this relevant?